A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies.
G CuriglianoM M JimenezT ShimizuB KeamF Meric-BernstamA RuttenJ GlaspyP J SchulerN S ParikhM IsingN HassounahJ WuM LeykX ChenH BurksA ChaudhuryJ OteroE Garralda CabanasPublished in: ESMO open (2024)
LHC165 demonstrated acceptable safety and tolerability both as SA and in combination with spartalizumab, and evidence of limited antitumor activity was seen in adult patients with relapsed/refractory or metastatic solid tumors.